[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Jazz Pharmaceuticals Plc (JAZZ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

November 2018 | 95 pages | ID: J3328161188EN
GlobalData

US$ 250.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Summary

Jazz Pharmaceuticals plc (Jazz Pharmaceuticals) is a specialty biopharmaceutical company which identifies, develops and commercializes medicines with focus on narcolepsy, cancer, pain and psychiatry. Its major marketed products include Xyrem, sodium oxybate oral solution, for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze, an asparagine specific enzyme, for acute lymphoblastic leukemia; Prialt, ziconotide, for severe chronic pain in patients who are intolerant or refractory to other treatments and FazaClo orally disintegrating clozapine tablets indicated for the treatment of resistant schizophrenia. The company sells its products through a network of local distributors and wholesalers. It has operations in the US and Europe. Jazz Pharmaceuticals is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals Plc (JAZZ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
  • The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
  • The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
  • Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
  • Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
  • Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company.
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018
Jazz Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details
Asset Purchase
JAZZ Pharma Acquires Rare Pediatric Disease Priority Review Voucher from Spark Therapeutics for USD110 Million
Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million
Jazz Pharma Acquires Rights To ADX-N05 From Aerial BioPharma For US$125 Million
Venture Financing
Arrivo BioVentures Raises USD49 Million in Venture Financing
Alize Pharma Raises USD1.9 Million in Venture Financing
Alize Pharma Raises USD6.4 Million in Series A Financing
Celator Pharma Raises US$39 Million In Venture Financing
Celator Pharma Raises USD4.1 Million in Venture Financing
Alize Pharma Raises US$4 Million In Venture Financing
Partnerships
Jazz Pharma and MD Anderson Cancer Center Enter into Agreement
Jazz Pharma and ImmunoGen Enter into Research and Option Agreement
The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351
Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide
Merger
Jazz Pharma Merges With Azur Pharma In All Stock Transaction
Licensing Agreements
Jazz Pharma Enters into License Agreement with XL-protein
Nippon Shinyaku Enters into Licensing Agreement with Jazz Pharma
Jazz Pharma Amends Licensing Agreement with Pfenex
Alize Pharma Enters into Licensing Agreement with New Paradigm Therapeutics
Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323
EUSA Pharma Enters Into Licensing Agreement With Alize Pharma For ASPAREC
Equity Offering
Celator Pharma Raises USD43.7 Million Public Offering of Shares for
Celator Pharma Raises USD15 Million in Public Offering of Shares and Warrants
Debt Offering
Jazz Pharma Raises USD575 Million in Private Placement of Notes Due 2024
Jazz Pharma Raises USD575 Million in Private Placement of 1.875% Senior Notes Due 2021
Asset Transactions
TerSera Therapeutics to Acquire Prialt from Jazz Pharma for USD80 Million
Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma
Aytu BioScience Acquires ProstaScint from Jazz Pharma
Essex Bidco Acquires Assets from Jazz Pharma
Lantheus Medical Imaging Acquires Quadramet from Jazz Pharma
Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For US$95 Million
Acquisition
Jazz Pharma Completes Tender Offer to Acquire Celator Pharma
Jazz Pharma Acquires Alize Pharma
AstraZeneca May Acquire Ariad Pharma
Jazz Pharma Completes Acquisition Of Majority Interest In Gentium For US$993.4 Million
Jazz Pharma Acquires Eusa Pharma For Up To US$730 Million
Jazz Pharmaceuticals Plc - Key Competitors
Jazz Pharmaceuticals Plc - Key Employees
Jazz Pharmaceuticals Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Financial Announcements
Nov 06, 2018: Jazz Pharmaceuticals announces third quarter 2018 financial results
Aug 07, 2018: Jazz Pharmaceuticals announces second quarter 2018 financial results
May 08, 2018: Jazz Pharmaceuticals Reports First Quarter 2018 Financial Results
Feb 27, 2018: Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2017 Financial Results
Nov 07, 2017: Jazz Pharmaceuticals Announces Third Quarter 2017 Financial Results
Aug 08, 2017: Jazz Pharmaceuticals Announces Second Quarter 2017 Financial Results
May 09, 2017: Jazz Pharmaceuticals Announces First Quarter 2017 Financial Results
Feb 28, 2017: Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2016 Financial Results
Corporate Communications
Dec 04, 2017: Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer
Product News
08/03/2017: Jazz Pharmaceuticals Announces FDA Approval of Vyxeos Liposome for Injection for the Treatment of Adults with Newly-Diagnosed Therapy-Related Acute Myeloid Leukemia (t-AML) or AML with Myelodysplasia-Related Changes (AML-MRC)
08/03/2017: Jazz Pharmaceuticals Announces Webcast for Vyxeos Investor Update
03/19/2018: Clinigen appointed by Jazz Pharmaceuticals to manage Managed Access Program for Vyxeos (CPX-351) outside the United States
02/08/2018: National Comprehensive Cancer Network adds Jazz Pharmaceuticals' Vyxeos (daunorubicin and cytarabine) Liposome for Injection to Clinical Practice Guidelines in Oncology
Product Approvals
Nov 03, 2017: Jazz Pharmaceuticals Submits Vyxeos Marketing Authorization Application to European Medicines Agency for Treatment of Certain Types of High-Risk Acute Myeloid Leukemia
May 31, 2017: Jazz Pharmaceuticals Announces FDA Acceptance of NDA for VYXEOS (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia, with Priority Review Status
Apr 03, 2017: Jazz Pharmaceuticals Completes Rolling Submission of New Drug Application for Vyxeos (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia
Clinical Trials
Nov 01, 2017: Jazz Pharmaceuticals to Present Abstracts on Vyxeos at ASH 2017 Annual Meeting
Jan 17, 2017: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2017
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Jazz Pharmaceuticals Plc, Deals By Therapy Area, 2012 to YTD 2018
Jazz Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018
JAZZ Pharma Acquires Rare Pediatric Disease Priority Review Voucher from Spark Therapeutics for USD110 Million
Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million
Jazz Pharma Acquires Rights To ADX-N05 From Aerial BioPharma For US$125 Million
Arrivo BioVentures Raises USD49 Million in Venture Financing
Alize Pharma Raises USD1.9 Million in Venture Financing
Alize Pharma Raises USD6.4 Million in Series A Financing
Celator Pharma Raises US$39 Million In Venture Financing
Celator Pharma Raises USD4.1 Million in Venture Financing
Alize Pharma Raises US$4 Million In Venture Financing
Jazz Pharma and MD Anderson Cancer Center Enter into Agreement
Jazz Pharma and ImmunoGen Enter into Research and Option Agreement
The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351
Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide
Jazz Pharma Merges With Azur Pharma In All Stock Transaction
Jazz Pharma Enters into License Agreement with XL-protein
Nippon Shinyaku Enters into Licensing Agreement with Jazz Pharma
Jazz Pharma Amends Licensing Agreement with Pfenex
Alize Pharma Enters into Licensing Agreement with New Paradigm Therapeutics
Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323
EUSA Pharma Enters Into Licensing Agreement With Alize Pharma For ASPAREC
Celator Pharma Raises USD43.7 Million Public Offering of Shares for
Celator Pharma Raises USD15 Million in Public Offering of Shares and Warrants
Jazz Pharma Raises USD575 Million in Private Placement of Notes Due 2024
Jazz Pharma Raises USD575 Million in Private Placement of 1.875% Senior Notes Due 2021
TerSera Therapeutics to Acquire Prialt from Jazz Pharma for USD80 Million
Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma
Aytu BioScience Acquires ProstaScint from Jazz Pharma
Essex Bidco Acquires Assets from Jazz Pharma
Lantheus Medical Imaging Acquires Quadramet from Jazz Pharma
Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For US$95 Million
Jazz Pharma Completes Tender Offer to Acquire Celator Pharma
Jazz Pharma Acquires Alize Pharma
AstraZeneca May Acquire Ariad Pharma
Jazz Pharma Completes Acquisition Of Majority Interest In Gentium For US$993.4 Million
Jazz Pharma Acquires Eusa Pharma For Up To US$730 Million
Jazz Pharmaceuticals Plc, Key Competitors
Jazz Pharmaceuticals Plc, Key Employees
Jazz Pharmaceuticals Plc, Other Locations
Jazz Pharmaceuticals Plc, Subsidiaries

LIST OF FIGURES

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Jazz Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12


More Publications